Showing results (61-70 of 124) with videos related to
Sort By:
Pageof 13
Breast Cancer Research and Treatment|February 7, 2018
First-line ribociclib plus letrozole in postmenopausal women with HR+ , HER2- advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trialWolfgang Janni, Emilio Alba, Thomas Bachelot, et al.Plos One|December 30, 2008
Angiogenesis-related gene expression profile with independent prognostic value in advanced ovarian carcinomaMarta Mendiola, Jorge Barriuso, Andrés Redondo, et al.Clinical Breast Cancer|January 26, 2019
Phase II, Multicenter, Single-arm Trial of Eribulin as First-line Therapy for Patients With Aggressive Taxane-pretreated HER2-Negative Metastatic Breast Cancer: The MERIBEL StudyVanesa Ortega, Antonio Antón, Isabel Garau, et al.Plos One|June 12, 2020
Bayesian networks established functional differences between breast cancer subtypesLucía Trilla-Fuertes, Angelo Gámez-Pozo, Jorge M Arevalillo, et al.Journal of Plant Research|March 11, 2023
Geographic isolation and long-distance gene flow influence the genetic structure of the blue fan palm Brahea armata (Arecaceae)Jessica Pérez-Alquicira, Elisabet V Wehncke, Gustavo A García-Loza, et al.Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|June 17, 2023
Efficacy of second and third lines of treatment in advanced soft tissue sarcomas: a real-world studyLaura Gutierrez-Sainz, Sara Martinez-Fdez, Jorge Pedregosa-Barbas, et al.JAMA Oncology|October 7, 2021
Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor-Positive, ERBB2-Negative Advanced Breast Cancer: A Randomized Clinical TrialAntonio Llombart-Cussac, José Manuel Pérez-García, Meritxell Bellet, et al.Journal of Drug Assessment|May 10, 2019
Broad consensus on the optimal sequence for the systemic treatment of metastatic breast cancer: results from a survey of Spanish medical oncologistsPedro Sánchez-Rovira, Pilar Zamora, Javier Salvador-Bofill, et al.Breast (Edinburgh, Scotland)|June 16, 2024
Impact of coadministration of proton-pump inhibitors and palbociclib in hormone receptor-positive/HER2-negative advanced breast cancerSerena Di Cosimo, José Manuel Pérez-García, Meritxell Bellet, et al.European Journal of Preventive Cardiology|February 24, 2021
Cardiovascular risk factors during cancer treatment. Prevalence and prognostic relevance: insights from the CARDIOTOX registryJuan Caro-Codón, Teresa López-Fernández, Carlos Álvarez-Ortega, et al.Pageof 13